Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

Board Meeting For The Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2017 And Intimation Of Closure Of Trading Window.

 This is to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Friday, November 10, 2017, inter alia, to consider and take on record the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2017. Please be informed that the Trading Window for trading in the Equity shares of the Company will be closed from October 31, 2017 to November 12, 2017, both days inclusive.
30-10-2017
Bigul

Health ministry can invoke provision of Patent Act to reduce cost of procurement of Prevnar 13 under UIP: says Dr Nair

 Even though the Indian patent office has granted Pfizer a patent for Prevnar 13 pneumonia vaccine making it unaffordable for many, the Union health ministry can invoke government use provision under section
30-10-2017
Bigul

Pneumonia vaccine case traces the fine line on public health

 The legal battle that brews over Pfizer's pneumococcal vaccine in India is set to create a benchmark of sorts for vaccines in the arena of public health. Until now, innovation, access and...
27-10-2017
Bigul

Pfizer to start auction process for its consumer healthcare unit in Nov

 The prospective sale was first mooted on Oct 10, when Pfizer said it was considering strategic options for the unit
26-10-2017
Bigul

How UCLA is fighting proxy patent battle for expensive cancer drug in India

 UCLA appears to be representing the pharma firms Pfizer, Medivation and Astellas in its battle. They aren't telling the Delhi high court about this
18-10-2017

PanaceaBiotec, MSFIndia oppose Pfizer's pneumonia vaccine patent

 Panacea Biotec files a review petition with the patent office seeking revocation of the patent given to Pfizer; MSF India moves Delhi high court to overturn patent
13-10-2017
Bigul

Company news

 Pfizer plans strategic alternatives for its consumer healthcare business, including full or partial separation of the segment through a spin-off, sale or other transaction, the company said in a...
11-10-2017
Bigul

Press Release / Media Release

 Pfizer Limited has been informed by its parent company Pfizer Inc., USA, that they are reviewing strategic alternatives for its global Consumer Healthcare Business. A copy of the press release dated October 10, 2017, issued by Pfizer Inc., USA informing the same is attached for reference. We request you to kindly take the same on record.
11-10-2017

Pfizer mulls options for consumer healthcare business

 Pfizer Inc. said it was reviewing options for its consumer healthcare business, including a full or partial separation of the unit
10-10-2017
Bigul

Sub: Compliance Certificate - Regulation 40(9) Of The SEBI (LODR) Regulations, 2015

 In compliance with Regulation 40 (9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith the Certificate given by the Practicing Company Secretary, M/s. Manish Ghia & Associates, for the half year ended September 30, 2017.
09-10-2017
Next Page
Close

Let's Open Free Demat Account